Kornimate/medical-research-clean huggingface dataset:
prep (pre-exposure prophylaxis) stigma and women ethnodrama pre-test phase

Conditions: HIV

Summary: the investigators will develop and pre-test an ethnodrama intervention designed to transform community member beliefs about and foster support of young cisgender women (ycw) using prep.

in aim 1/year 1, the investigators will develop the ethnodrama intervention; no data collection activities are included. in aim 2/year 2, the investigators will pre-test the ethnodrama intervention with invited groups of young women and members of young women's socio ecology (i.e., male partners, female peers, healthcare providers, informal community leaders, and family members).

Eligibility criteria:
inclusion criteria: * 18 years of age or older * young cisgender women who have taken or are taking prep * male partners of young women * female peers of young women * healthcare providers * informal community leaders * family members of young women exclusion criteria: none

Keywords: stigma hiv prep
standard implants with bone regeneration vs short implants

Conditions: Implant Complication; Bone Resorption

Summary: a study designed as a randomized controlled trial of parallel group design will be conducted at the dental clinic of the university of valencia to compare, considering different parameters, the rehabilitation with dental implants of atrophic posterior mandibles or maxillae using short implants or longer implants with vertical bone regeneration with gbr. the hypothesis of the study is that both treatment options will be successful to rehabilitate atrophic posterior mandibles or maxillae. moreover, more surgical complications will be encountered in the bone regeneration group.


Eligibility criteria:
inclusion criteria: * all the patients with a distal edentulism kennedy -applegate class ii in the posterior mandible or maxilla, with residual bone height from the top of the crest to the opposite landmark (the alveolar nerve for the lower and the sinus cavity for the upper) between 5 and 7 millimeters. the bone peak on the last tooth before the edentulous space must be positioned from 2 to 4 mm from the cej. (x-ray evaluation by periapical film on a rinn holder). * all patients with at least 3 mm of keratinized tissue on the edentulous crest. in case of absence of this prerequisite, three months before the keratinized tissue is augmented by a ephytelium-connective tissue graft harvested from the palate. * patients with edentulous distal sites exclusion criteria: * heavy smokers (more than 10 cigarettes /day) * patients with active periodontal disease: full mouth plaque index (fmpi \> 20%) and full mouth bleeding index (fmbi \> 20%). * patients with less of 5 mm of bone width. * patients with systemic conditions or under prescription of medications that contraindicate oral surgery
effectiveness of parenting intervention for improving child mental health

Conditions: Behavior Problem; Conduct Disorders in Children; Mental Health Wellness 1

Summary: in this study, effectiveness of a group parenting intervention was assessed in a community setting, for its impact on child behaviour problems and parental mental health.


Eligibility criteria:
inclusion criteria: * parents who consented to join the trial * children aged 2-8 years * mean score on the eyberg intensity scale for clinical issues exclusion criteria: * any comorbid psychiatric condition in parents or children * substance abuse or diagnosed clinical somatic condition influencing ability to consent or follow intervention
comparing erector spinae plane (esp) and thoracic paravertebral (tpv) block analgesic effect after elective vats

Conditions: Surgery; Thoracic

Summary: the aim of the study is to compare two different locoregional techniques in vats.

there are clear clinical and logistic reasons for pursuing the best possible post-operative pain management avoiding the negative side effects of opioid treatment; in order to garantee an enhanced recovery after surgery. a short hospital stay is fundamental to reduce patient morbidity and costs. regional anesthetic nerve blocks are an ideal option to achieve this goal. paravertebral block serves as an ideal approach for thoracic and abdominal surgery through delivering segmental anesthesia of operative sites. thoracic paravertebral block has superior analgesia as well as fewer complications than systemic opioids. it has been successfully applied in sternotomy, breast surgery, abdominoplasty, and laparoscopic cholecystectomy. esp block is a recently described technique, with promising results in different scenarios. it probabily has a better risk profile than pvb, for its lower possibility of accidental pleural puncture and reabsorption of local anesthtetic than pvb one

Eligibility criteria:
inclusion criteria: * patients over 18 year of age undergoing elective vats lung resection at orbv exclusion criteria: * patients with inability to consent, contraindications to standard care, or factors that can cause bias in interpretation, absolute contraindications to the regional anesthesia techniques studied (patient's refusal, allergy to local anesthetics, infections in the site of injection). pregnant women are not a target study-group so they are excluded for design simplification. conversion to the open technique will be a post-randomization exclusion factor concerning the main outcomes
evaluation of the long-term persistence of hepatitis a antibodies in healthy adults who were vaccinated 21-25 years earlier with glaxosmithkline (gsk) biologicals' hepatitis a vaccine, havrix®

Conditions: Hepatitis A

Summary: the purpose of this study is to assess the long-term persistence of immunity to hepatitis a in adults who were vaccinated 21-25 years earlier with hepatitis a vaccine, havrix®.

this is a long-term persistence study in which subjects who participated in the primary studies hav-112 (208109/108) or hav-123 (208109/114) and did not receive an additional dose of hepatitis a vaccine since then, will be invited to provide a blood sample at years 21 to 25 after their second vaccine dose. no vaccine will be administered during the study period.

Eligibility criteria:
inclusion criteria: * a male or female who received two doses of havrix in study hav-112 (208109/108) or hav-123 (208109/114), and received no further booster dose since then. * subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. return for follow-up visits). * written informed consent obtained from the subject. exclusion criteria: * history of hepatitis a disease since completion of the primary vaccination series in studies hav-112 (208109/108) or hav-123 (208109/114). * administration of a hepatitis a vaccine at any time since completion of the primary vaccination series in studies hav-112 (208109/108) or hav-123 (208109/114) including a challenge dose of the study vaccine, as a part of the study procedures, during the long-term persistence phase. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history. * administration of hepatitis a immunoglobulins and/or any blood products and/or long-acting immune-modifying drugs within six months prior to study entry. * chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to study entry. for corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent. inhaled and topical steroids are allowed. * administration of long-acting immune-modifying drugs within six months prior to study entry (e.g. infliximab). * concurrently participating in another clinical study during the period starting 30 days before and ending 30 days after each study visit, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).

Keywords: long-term persistence havrix hepatitis a
to determine the gait and functional improvement in total knee arthroplasty

Conditions: Degenerative Arthritis

Summary: this is an observational study to understand the effects of soft-tissue balancing on gait, function and rehabilitation potential after sensor-assisted total knee arthroplasty

the primary objectives of this study are to understand the effects of soft-tissue balancing on gait, function and rehabilitation potential after sensor-assisted total knee arthroplasty and to correlate intra-operative subjective feel with orthosensor outputs secondary objectives are to quantify and observe pain medication use, swelling, muscle strength and girth, gait efficiency, patient satisfaction, activity levels, functional return (i.e., back to work, resume normal activities) and patient perception of a balanced knee

Eligibility criteria:
inclusion criteria: * subject must be a candidate for a primary pcl retaining total knee arthroplasty * subject must be diagnosed with one or more of the following conditions: 1. osteoarthritis 2. avascular necrosis 3. rheumatoid or other inflammatory arthritis 4. post-traumatic arthritis minimum age: 45 maximum age: 80 * subject is likely to be available for all study visits * subject is able and willing to sign the informed consent and follow study procedures exclusion criteria 1. prior total knee arthroplasty 2. ligament insufficiencies 3. prior surgeries such as: 1. acl or pcl reconstructions 2. posterolateral reconstructions 3. osteotomies 4. tibia plateau fractures 5. range of motion less than 90 degrees f ) flexion contracture of more than 20 degrees
a study of peginterferon alfa-2a [pegasys] in patients with chronic hepatitis b who are hbeag positive

Conditions: Hepatitis B, Chronic

Summary: this open-label, multi-center study will evaluate the effect on the quantitative hbsag reduction of peginterferon alfa-2a \[pegasys\] in patients with hbeag positive chronic hepatitis b. patients will receive pegasys 180 mcg sc once weekly. after 24 weeks of treatment, rapid responders will receive another 24 weeks of treatment. after 24 weeks of treatment, slow responders will be randomized to another 24 or 72 weeks of pegasys monotherapy, or to 72 weeks pegasys plus 36 weeks adefovir (10 mg, po once daily, starting from week 29 of pegasys treatment). the anticipated time on study drug is \>2 years.


Eligibility criteria:
inclusion criteria: * adult patients \>/=18 years of age * hbeag positive chronic hepatitis b * compensated liver disease exclusion criteria: * patients who had previously received treatment of drugs with activity against hbv within 6 months prior to study start * antiviral, anti-neoplastic or immunomodulatory treatment * co-infection with active hepatitis a, hepatitis c, hepatitis d, or hiv * evidence of decompensated liver disease * chronic liver disease other than viral hepatitis
exploration of dna methylation as a marker for early detection of high grade serous epithelial ovarian cancer

Conditions: Epithelial Ovarian Cancer

Summary: the purpose of this study is to determine if there are markers in plasma that can be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.

this study has two phases: "discovery" cohort and "validation" cohort. the "discovery" phase of this study will obtain tissue samples in a retrospective manner. the investigators will perform genome-scale dna methylation analysis to obtain a panel of candidate methylated dna biomarkers. twenty archival primary serous epithelial ovarian cancer and twenty archival normal ovarian and salpingeal tissues will be identified by running a report of diagnosis. during the "validation" phase of this study, blood and tissue samples will be obtained in a prospective manner. the patients will be undergoing consultation for undiagnosed pelvic mass and are being scheduled for a diagnostic laparoscopic biopsy. at the time of their consultation, patients will be recruited and consented for this phase of the study.

Eligibility criteria:
inclusion criteria: * female * 18 years of age and older * women with an undiagnosed pelvic mass who need to undergo diagnostic laparoscopic surgery exclusion criteria: * male * under 18 years of age * women who can not give informed consent

Keywords: dna methylation dna biomarkers pelvic mass
headless screw fixation for metacarpal fractures in adults.

Conditions: Metacarpal Fractures in Adults

Summary: the goal of this study is to evaluate results of intramedullary screw fixation of metacarpal fractures while summarizing the pearls and pitfalls to maximize successful surgical outcomes in adults, metacarpal fractures are third most common upper extremity fractures, intramedullary screw fixation is a fixation option that offers rigid stability, early active range of motion, and simplicity of insertion,


Eligibility criteria:
inclusion criteria: * adult patients. * metacarpal shaft fractures. * simple fractures. * recent fractures within 1-2 weeks. * isolated metacarpal fractures. exclusion criteria: * pediatric fractures with open physis. * head-splitting fractures and metacarpal basal fractures. * compound fracture increasing risk of infection. * medical illness or mental disorders affecting the follow-up examination. * association with other fractures fixed by methods that limit early range of motion. * pathologic fractures.
analgesia in knee arthroscopic surgery

Conditions: Postoperative Pain

Summary: pain relief in knee arthroscopic surgery is essential for rapid recovery of function.

intra-articular analgesia is useful in reducing patients' postoperative disability. it anticipates and prevents the onset of pain, and helps avoid the need for additional drugs. usually it is possible to reach good analgesia in the immediate postoperative period by the administration of analgesic drugs. recently, intra-articular administration of different anaesthetic substances with a local action (e.g. bupivacaine) has been introduced in clinical practice. the aim of the administration of these substances should not be the reduction of postoperative pain, but its prevention.

Eligibility criteria:
inclusion criteria: * patients scheduled for knee arthroscopy under spinal anaesthesia exclusion criteria: * diabetes mellitus * contraindication to spinal anesthesia * patient refusal
activation of alternative cellular energy (ace) pathway in the therapy of herpes virus infections

Conditions: Herpes Simplex; Herpes Zoster

Summary: the research question to be addressed is whether indirect phototherapy based activation of the body's alternative cellular energy (ace) pathway will lead to expedited healing of active herpes simplex virus (hsv) and herpes zoster virus (hzv)skin lesions, and also possibly inhibit both latent hsv infections and residual hzv infections.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of active, latent or residual hsv or hzv infection exclusion criteria: * unwilling or unable to provide informed consent

Keywords: herpes hsv zoster hzv shingles
a study to evaluate the effect of single doses of drug a (lamotrigine) and drug b (vofopitant) alone and in combination on resting motor threshold in healthy subjects

Conditions: Bipolar Disorder

Summary: the purpose of this study is to investigate the effect of drug a on its own and when it is given in combination with drug b on markers of brain activity. the study will 1. assess the effects of drug a and drug b on muscle movement after brain stimulation; 2. examine how the body handles (absorbs, distributes, breaks down and gets rid of) drug a and drug b when given in combination; 3. examine the safety of drug a and drug b when given together.


Eligibility criteria:
inclusion criteria: * healthy subject * male aged 18-65 * greater than 50kg weight * bmi 19-29.9 kg/m2 exclusion criteria: * positive drug/alcohol screen * positive hiv antibody * history of drug dependence * history of neurological disease * pacemaker * smoker

Keywords: healthy volunteer resting motor threshold (rmt) transcranial magnetic stimulation (tms)
the significance of funguria in hospitalized patients

Conditions: Urinary Tract Infections

Summary: this investigation is a epidemiologic case-control study of the risk factors associated with nosocomial funguria (fungi in the urine).

a recent large multi-center national surveillance survey of almost 5000 nosocomial (hospital based) urine isolates from medical intensive care units demonstrated that fungi comprised nearly 40% of urine isolates. little is known about distinguishing fungi that cause colonization from those causing infection. the objective of this study is to define the epidemiology of nosocomial funguria and natural history of patients that develop funguria while hospitalized. patients who may have eligible for this study will be identified from microbiology laboratory specimens at the harbor-ucla medical center and cedars-sinai medical center.

Eligibility criteria:
inclusion criteria: * patients hospitalized at least 12 hours of any age (\ 100 years of age) and a urine or blood culture positive for fungi, or urine culture negative for fungi (control group) exclusion criteria: * patients already surveyed for funguria during current hospitalization and patients already being followed for recognized funguria

Keywords: funguria epidemiology urinary tract infections
safety and pharmacokinetics of odm-208 in patients with metastatic castration-resistant prostate cancer

Conditions: Prostate Cancer Metastatic

Summary: the purpose of this first-in-man study is to evaluate safety and tolerability of odm-208 in patients with metastatic castration-resistant prostate cancer.

safety and tolerability profile of odm-208 will be explored

Eligibility criteria:
main inclusion criteria: * written informed consent (ic) obtained. * male aged ≥ 18 years. * histologically confirmed adenocarcinoma of the prostate. * castration resistant prostate cancer with serum testosterone \< 50 ng/dl. * metastatic disease. * ongoing androgen deprivation therapy with gnrh analogue or antagonist, or have had bilateral orchiectomy. * received at least one prior line of novel hormonal androgen receptor (ar) targeted therapy (e.g. abiraterone, enzalutamide). * ecog performance status 0-1. * adequate marrow, liver and kidney function. * able to swallow study treatment. * part 1: treatment with at least 1 line of chemotherapy or ineligibility for chemotherapy. part 2: treatment with at least 1 line of taxane-based chemotherapy in castration-sensitive prostate cancer (cspc) or in crpc. main exclusion criteria: * history of pituitary or adrenal dysfunction. * known brain metastases or active leptomeningeal disease. * active infection or other medical condition that would make corticosteroid contraindicated. * poorly controlled diabetes. * hypotension or uncontrolled hypertension. * clinically significantly abnormal serum potassium or sodium level. * active or unstable cardio/cerebro-vascular disease including thromboembolic events. * prolonged qtcf interval.
online adaptive radiotherapy cervical cancer with reduced margin for cervical cancer

Conditions: Uterine Cervical Neoplasm

Summary: online adaptive radiotherapy (oart) has demonstrated to be feasible to reduce planning target volume (ptv) margins for cervical cancer. to explore the value of reduced margins in oart for cervical cancer, we conducted a prospective clinical trial to determine the clinical efficacy and toxicity of reduced margins.

this is an investigator-initiated efficacious, single-center, open-label clinical trial study. this study hypothesizes that the use of reduced ptv margins in oart for cervical cancer could decrease toxicity and achieve more accurate dosimetric coverage. a dose of 50.4 gy is delivered to clinical target volume (ctv) with reduced margin oart. patients receive cisplatin based concurrent chemotherapy. the primary endpoint is acute toxicity.

Eligibility criteria:
inclusion criteria: 1. patients must be informed of the investigational nature of this study and give written informed consent before treatment. 2. age ≥18 years and ≤ 75 years. 3. patients with newly histologically confirmed cervical cancer, including squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma, et al. 4. no evidence of para-aortic metastatic lymph nodes (mlns) and inguinal lymph nodes on ct, mri or positron emission tomograph (pet)/ct. 5. no contraindications to ct scanning. 6. no evidence of distant metastasis (figo stage ivb). 7. adequate marrow: neutrophile granulocyte count ≥1.5\*10\^9/l, hemoglobin ≥ 80 g/l, platelet count ≥100\*10\^9/l. 8. normal liver and kidney function: creatinine (cr) \< 1.5 mg/dl, alanine aminotransferase (alt), aspartate aminotransferase (ast) \< 2\*upper limit of normal (uln). exclusion criteria: 1. with common iliac mlns. 2. tumor extended to the lower third of the vagina. 3. tumor spread to mucosa of the bladder or rectum. 4. prior surgery (including pelvic or para-aortic lymph nodes resection, except for tumor biopsy), radiotherapy or chemotherapy to primary tumor or nodes. 5. prior malignancy. 6. history of previous radiotherapy to the abdomen or pelvis. 7. pregnancy or lactation. 8. active inflammatory bowel disease, or history of severe stomach or duodenal ulcer. 9. active infection with fever. 10. patients with unacceptable risk that intracavitary brachytherapy can not be conducted. 11. any severe disease which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control, and emotional disturbance.

Keywords: uterine cervical neoplasm online adaptive radiotherapy
metabolic exercise testing

Conditions: Metabolic Myopathies; Exercise Test; Myalgia

Summary: exertional symptoms are the hallmarks of metabolic myopathies, supporting the concept of using functional tests when this diagnosis is suspected. exercise increases the concentration of muscle metabolites in the venous blood supply (e.g. lactate, pyruvate, and ammonia) especially during recovery. the purpose of this study is to compare the results of exercise testing with to the data from muscle biopsy or genetic analysis.


Eligibility criteria:
inclusion criteria: * referred to the physiology department of brest hospital for a metabolic exercise test * ability to provide informed consent exclusion criteria: * contraindication(s) to perform cardiopulmonary exercise testing (ats/accp statement on cardiopulmonary exercise testing, am j respi care med 167: 211-77, 2003) * pregnancy or unknown pregnancy status.

Keywords: metabolic myopathies exercise testing blood sample muscle biopsy genetic analysis cycloergometer grip-test exercise physiology muscle physiology
effect of cpap on postoperative delirium

Conditions: Sleep Apnea, Obstructive; Delirium

Summary: patients with a medical condition known as obstructive sleep apnea may be at increased risk of delirium following surgery. this study loans autotitrating cpap machines to randomly-selected patients who are at high-risk for obstructive sleep apnea with the goal of preventing post-operative delirium.

patients undergoing elective knee and hip replacements will be prospectively enrolled. these surgical procedures all have an expected length of stay \> 3 days. immediately following enrollment, patients will be randomized to receive cpap or routine peri-operative care. patients in the cpap group will be instructed to wear an autotitrating positive airway pressure (apap) device any time they sleep prior to surgery and on postoperative days 0, 1, and 2.

Eligibility criteria:
inclusion criteria: * age 50 and above * scheduled for an elective knee or hip replacement * ability to speak english and give informed consent * at risk for obstructive sleep apnea as defined by a stop-bang score \> 2 exclusion criteria: * history of psychiatric or neurologic illness that would confound delirium assessment * severe tracheal or lung disease * contraindications to face-mask cpap * treated osa